A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06651600 In Healthy Japanese Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06651600 In Healthy Japanese Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs PF 6651600 (Primary)
  • Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Nov 2017 to 22 Nov 2017.
    • 12 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 27 Oct 2017.
    • 12 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top